JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$9.74B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$8.51B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$6.03B |
| 4 |
SPYM
State Street SPDR Portfolio S&P 500 ETF
SPYM
|
+$4.86B |
| 5 |
Meta Platforms (Facebook)
META
|
+$4.05B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.63B |
| 2 |
Vanguard Tax-Exempt Bond Index Fund
VTEB
|
+$3.02B |
| 3 |
Palantir
PLTR
|
+$2.14B |
| 4 |
Shopify
SHOP
|
+$2.1B |
| 5 |
Robinhood
HOOD
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 25.29% |
| 2 | Technology | 22.42% |
| 3 | Healthcare | 8.64% |
| 4 | Financials | 8.63% |
| 5 | Consumer Discretionary | 8.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3926
CALL
Roivant Sciences
ROIV
$25.8B
| $2.08M | ﹤0.01% |
78,900
| – | – |
2025 Q3
2 quarters
|
|
|
HTO
3927
H2O America
HTO
$2.52B
| $2.08M | ﹤0.01% |
35,284
-10,432
| -23% | -$568K |
2016 Q4
37 quarters
|
|
3928
Goldman Sachs Access Investment Grade Corporate Bond ETF
GIGB
$950M
| $2.07M | ﹤0.01% |
45,431
-1,094
| -2% | -$50.6K |
2023 Q3
10 quarters
|
|
3929
Invesco S&P 500 Equal Weight Utilities ETF
RSPU
$477M
| $2.06M | ﹤0.01% |
25,457
+1,166
| +5% | +$92.3K |
2024 Q3
6 quarters
|
|
3930
CALL
Tapestry
TPR
$23.6B
| $2.05M | ﹤0.01% |
15,000
-115,000
| -88% | -$16.3M |
2024 Q4
5 quarters
|
|
3931
Credit Acceptance
CACC
$5.48B
| $2.05M | ﹤0.01% |
4,864
-75
| -2% | -$35.4K |
2013 Q2
51 quarters
|
|
3932
Westlake Chemical Partners
WLKP
$750M
| $2.05M | ﹤0.01% |
94,105
-350
| -0.4% | -$7.51K |
2021 Q3
18 quarters
|
|
|
MUND
3933
Northern Trust 2055 Tax-Exempt Distributing Ladder ETF
MUND
$3.87M
| $2.04M | ﹤0.01% |
20,000
| – | – |
2025 Q3
2 quarters
|
|
3934
CALL
Air Products & Chemicals
APD
$61.8B
| $2.04M | ﹤0.01% |
7,000
| – | – |
2025 Q3
2 quarters
|
|
3935
Tarsus Pharmaceuticals
TARS
$3.42B
| $2.04M | ﹤0.01% |
30,478
-26,168
| -46% | -$1.83M |
2020 Q4
21 quarters
|
|
3936
PGIM Portfolio Ballast ETF
PBL
$77.7M
| $2.04M | ﹤0.01% |
68,989
+43,754
| +173% | +$1.35M |
2025 Q4
1 quarter
|
|
3937
Amylyx Pharmaceuticals
AMLX
$3.55B
| $2.04M | ﹤0.01% |
159,663
+93,116
| +140% | +$1.31M |
2022 Q1
16 quarters
|
|
|
IEAGU
3938
Infinite Eagle Acquisition Corp Unit
IEAGU
$310M
| $2.03M | ﹤0.01% |
+200,000
| New | +$2.04M |
2026 Q1
0 quarters
|
|
|
NUVL
3939
CALL
DELISTED
Nuvalent
NUVL
| $2.03M | ﹤0.01% |
+21,000
| New | +$2.14M |
2026 Q1
0 quarters
|
|
|
NUVL
3940
PUT
DELISTED
Nuvalent
NUVL
| $2.03M | ﹤0.01% |
+21,000
| New | +$2.14M |
2026 Q1
0 quarters
|
|
3941
Vanda Pharmaceuticals
VNDA
$280M
| $2.03M | ﹤0.01% |
304,894
-91,123
| -23% | -$703K |
2015 Q4
41 quarters
|
|
3942
PUT
ResMed
RMD
$30.8B
| $2.02M | ﹤0.01% |
9,200
| – | – |
2025 Q2
3 quarters
|
|
3943
PUT
Full Truck Alliance
YMM
$8.48B
| $2.02M | ﹤0.01% |
+250,000
| New | +$2.38M |
2026 Q1
0 quarters
|
|
3944
Astec Industries
ASTE
$967M
| $2.02M | ﹤0.01% |
39,169
-152,329
| -80% | -$8.17M |
2016 Q4
37 quarters
|
|
3945
Red Violet
RDVT
$1.27B
| $2.01M | ﹤0.01% |
58,573
+34,619
| +145% | +$1.52M |
2021 Q4
17 quarters
|
|
3946
RXO
RXO
$3.86B
| $2.01M | ﹤0.01% |
146,325
-91,686
| -39% | -$1.35M |
2022 Q4
13 quarters
|
|
3947
Amphastar Pharmaceuticals
AMPH
$1.08B
| $2.01M | ﹤0.01% |
104,574
-54,070
| -34% | -$1.32M |
2014 Q3
46 quarters
|
|
3948
GeneDx Holdings
WGS
$2.18B
| $2.01M | ﹤0.01% |
33,674
+6,526
| +24% | +$595K |
2021 Q4
17 quarters
|
|
3949
PUT
Barclays
BCS
$79.1B
| $2.01M | ﹤0.01% |
+99,300
| New | +$2.42M |
2026 Q1
0 quarters
|
|
3950
Vanguard Intermediate-Term Tax-Exempt Bond ETF
VTEI
$1.53B
| $2M | ﹤0.01% |
+20,081
| New | +$2.04M |
2026 Q1
0 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2026 Portfolio in Review
As of Q1 2026, JP Morgan Chase held 8,085 positions worth $1.56T, down 2.2% from $1.59T the previous quarter. Its ten largest holdings account for 23% of the portfolio.
JP Morgan Chase deployed $90.5B of net new capital in Q1 2026, opening 727 new positions and adding to 3,199 existing holdings. Its largest new stake was iShares International Country Rotation Active ETF: 15,443,505 shares worth $481M.
By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 25% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Microsoft, an estimated $8.63B trimmed.
- JP Morgan Chase's largest Q1 2026 buy was iShares International Country Rotation Active ETF: 15,443,505 shares worth $481M.
- JP Morgan Chase added most to Vanguard S&P 500 ETF in Q1 2026, an estimated $9.74B increase.
- JP Morgan Chase's biggest Q1 2026 reduction was Microsoft, cutting an estimated $8.63B.
- JP Morgan Chase fully exited CyberArk in Q1 2026, selling an estimated $307M.
- JP Morgan Chase's ten largest holdings make up 23% of its $1.56T portfolio in Q1 2026.
- JP Morgan Chase opened 727 new positions and closed 604 in Q1 2026.
- JP Morgan Chase's portfolio value fell 2.2% quarter-over-quarter to $1.56T.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.